Based on these results and the differential cytotoxicity of 1 and 2 in patient-derived GBM cells (Figure 5B), one may expect that fine-tuning of the chemical structure would yield DYRK/CLK inhibitors with enhanced binding to the individual isoenzymes important in the specific tumor type. This evidence concerns the gene DYRK1A and neoplasm.